N-Acetylcysteine in Patients With Sickle Cell Disease (NAC)
N-Acetylcysteine in Patients With Sickle Cell Disease - Reducing the Incidence of Daily Life Pain
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Listed as NCT01849016, this PHASE3 trial focuses on Sickle Cell Disease and remains completed. Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), it has been updated 5 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- CHU Brugmann, Brussels
- Centre Hospitalier Régional de la Citadelle
- Centre Hospitalier Universitaire Saint Pierre
- Erasme University Hospital
- Erasmus Medical Center
- Fonds NutsOhra
- Guy's and St Thomas' NHS Foundation Trust
- Haga Hospital
- Queen Fabiola Children's University Hospital
- Stichting Janivo
- University Hospital St Luc, Brussels
- University Medical Center Groningen
- ZonMw: The Netherlands Organisation for Health Research and Development
For direct contact, visit the study record on ClinicalTrials.gov .